NEW YORK (GenomeWeb) – Shanghai-based biotechnology company Realbio Technology announced that it has raised RMB 40 million ($5.9 million) in a pre-A Series financing round.

Realbio, which was founded in 2014, uses high-throughput DNA sequencing technology to conduct microbiome studies and test clinical samples. It specializes in the enrichment and analysis of genes and microbiomes in fecal specimens. In an email to GenomeWeb, a company spokesman said Realbio uses Illumina platforms, mainly the HiSeq and MiSeq, to conduct its studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.